Fierce Pharma

NOVEMBER 18, 2022

Lilly wades deeper into copycat insulin market, scoring interchangeability tag for Lantus biosim. fkansteiner. Fri, 11/18/2022 - 11:01.

Insulin 90

Insulin Marketing 90

pharmaphorum

APRIL 11, 2024

Roche and Eli Lilly have been granted breakthrough status by the FDA for their pTau217 blood test for Alzheimer's disease.

117

117

XTalks

NOVEMBER 3, 2022

Eli Lilly is finding itself in an enviable position with its newly launched diabetes injection Mounjaro (tirzepatide) and blockbuster diabetes med Trulicity due to temporary shortages of competitor Novo Nordisk’s diabetes drug Ozempic (semaglutide). However, it’s uncertain whether Lilly will be able to keep pace with the newfound demand.

Sales 98

Sales FDA Approval Production Insulin 98

XTalks

APRIL 18, 2024

This test, which is being co-developed with Eli Lilly, has the potential to facilitate earlier and more accurate detection of the disease. Roche and Eli Lilly announced their partnership to develop the assay last year in March, which included launching a two-year clinical trial involving hundreds of volunteers.

Clinical Trials 52

Clinical Trials Clinical Trials In-Vitro Protein 52

pharmaphorum

DECEMBER 24, 2021

The anti-amyloid drug, which also claimed a breakthrough tag from the FDA in July, is being developed for the treatment of early-stage Alzheimer’s disease. The $56,000-a-year price tag for the drug, which has now been cut in half in the US, also hasn’t helped the drugmakers make a case for Aduhelm with US payers.

Drugs 109

Drugs FDA Approval Trials Marketing 109

Pharmaceutical Technology

MAY 15, 2023

Innovation S-curve for the pharmaceutical industry Peptide nano-particle conjugates is a key innovation area in the pharmaceutical industry By tagging peptides with nanoparticles, peptide nano-particle conjugates allow enhanced control over their biological behaviour, overcoming intrinsic limitations of the individual materials.

Antibody 130

Antibody DNA Development Vaccination 130

pharmaphorum

DECEMBER 17, 2021

Aduhelm (aducanumab) was approved by the FDA in June, but has been held back by a glacial rollout as clinicians have questioned the data on which the decision to clear the drug was based, plus a $56,000 per year price tag, which has in turn led to pushback by payers.

Trials 52

Trials Sales Marketing FDA Approval 52